

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Scheller, D. *et al.*
Serial No.: **10/565,699**
Filed: 25 January 2006
Title: USE OF ROTIGOTINE FOR THE TREATMENT OF DEPRESSION
Group Art Unit: 1627
Examiner: Carter, Kenda D.
Confirmation No.: 2513
Docket No.: **6102-000009/US/NP**
Client Ref.: **P/Sche/I/4/03**

SUBMITTED ELECTRONICALLY VIA EFS-WEB

10 February 2010

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT D AND RESPONSE TO OFFICE ACTION DATED 23 OCTOBER 2009
(INCLUDING PETITION FOR EXTENSION OF TIME)
(INCLUDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. §1.97(c))

This paper is in response to the Office Action dated 23 October 2009 issued in the above-identified patent application, in which a shortened statutory period of three (3) months was set for reply.

Applicant hereby makes petition for extension of time of one (1) month in which to submit the present response. Authorization is provided herewith to charge the fee required under 37 C.F.R. §1.17(a)(1) to Deposit Account No. **08-0750**.

This paper includes a supplemental information disclosure statement under 37 C.F.R. §1.97(c).

Serial No. 10/565,699

6102-000009/US/NP

Amendment D, Response to Office Action dated 23 October 2009, and Supplemental IDS
10 Feb 2010

AMENDMENT UNDER 37 C.F.R. §1.111 (AMENDMENT D)

Amendments IN THE CLAIMS are reflected in the listing of claims beginning on page 3 of this paper. No increase in total number of claims or in number of independent claims results from this amendment and no additional claim fees are believed payable.

REMARKS on the present amendment begin on page 11 of this paper.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT begins on page 19 of this paper.